Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Kraig Biocraft Laboratories (KBLB) Income from Continuing Operations (2016 - 2022)

Kraig Biocraft Laboratories (KBLB) has disclosed Income from Continuing Operations for 10 consecutive years, with 946847.0 as the latest value for Q4 2022.

  • Quarterly Income from Continuing Operations rose 18.67% to 946847.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was 3842014.0 through Dec 2022, up 52.25% year-over-year, with the annual reading at 3623353.0 for FY2025, 6.6% down from the prior year.
  • Income from Continuing Operations hit 946847.0 in Q4 2022 for Kraig Biocraft Laboratories, down from 810356.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 188590.0 in Q2 2018 to a low of 3187147.0 in Q3 2021.
  • Historically, Income from Continuing Operations has averaged 1004368.33 across 4 years, with a median of 940662.0 in 2021.
  • Biggest five-year swings in Income from Continuing Operations: skyrocketed 85.03% in 2018 and later plummeted 445.21% in 2019.
  • Year by year, Income from Continuing Operations stood at 494477.0 in 2018, then plummeted by 128.22% to 1128488.0 in 2019, then dropped by 3.17% to 1164219.0 in 2021, then grew by 18.67% to 946847.0 in 2022.
  • Business Quant data shows Income from Continuing Operations for KBLB at 946847.0 in Q4 2022, 810356.0 in Q3 2022, and 1038132.0 in Q2 2022.